| Literature DB >> 29028793 |
Edessa Negera1,2, Stephen L Walker1, Selfu Girma2, Shimelis N Doni3, Degafe Tsegaye3, Saba M Lambert3, Munir H Idriss2, Yohanis Tsegay2, Hazel M Dockrell1, Abraham Aseffa2, Diana N Lockwood1.
Abstract
BACKGROUND: Leprosy reactions are a significant cause of morbidity in leprosy population. Erythema nodosum leprosum (ENL) is an immunological complication affecting approximately 50% of patients with lepromatous leprosy (LL) and 10% of borderline lepromatous (BL) leprosy. ENL is associated with clinical features such as skin lesions, neuritis, arthritis, dactylitis, eye inflammation, osteitis, orchitis, lymphadenitis and nephritis. ENL is treated mainly with corticosteroids and corticosteroids are often required for extended periods of time which may lead to serious adverse effects. High mortality rate and increased morbidity associated with corticosteroid treatment of ENL has been reported. For improved and evidence-based treatment of ENL, documenting the systems affected by ENL is important. We report here the clinical features of ENL in a cohort of patients with acute ENL who were recruited for a clinico-pathological study before and after prednisolone treatment.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29028793 PMCID: PMC5656324 DOI: 10.1371/journal.pntd.0006011
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Demographic and clinical characteristics of study subjects at enrolment.
| Variables | ENL (n = 46) n (%) | LL (n = 31) n (%) | |
|---|---|---|---|
| Sex | Male | 31 (67.4) | 23 (74.2) |
| Female | 15 (32.6) | 8 (25.8) | |
| Median age in years (range) group | 27.5 (18–56) | 25.0 (18–60) | |
| Median age in years (range) Male | 28 (18–56) | 26.0 (18–60) | |
| Median age in years (range) Female | 26.7 (18–35) | 21.0 (18–30) | |
| MDT status | No previous MDT | 10 (21.7) | 22 (71.0) |
| Current | 9 (19.6) | 8 (25.8) | |
| Completed | 27 (58.7) | 1 (3.2) | |
| HIV status | Positive | 0 (0.0) | 0 (0.0) |
| Negative | 46 (100.0) | 31 (100.0) | |
| Duration of current ENL symptom (Episode) Mean ± SE [days] | 6.8 ±0.491 (range: 1–15) | - | |
| Clinical status at recruitment | |||
| ENL type | Acute | 23 (50.0) | - |
| Recurrent | 5 (10.9) | - | |
| Chronic | 18 (39.1) | - | |
| LL type | New | - | 23 (74.2) |
| Relapse | - | 5 (16.1) | |
| Defaulter | - | 3 (9.7) | |
| BI at diagnosis, Mean ± SE (range) | |||
| ENL | Acute | 3.9 ±0.205 (2–6) | - |
| Recurrent | 4.9 ±0.409 (4–6) | - | |
| Chronic | 3.7 ±0.103(3–4) | - | |
| LL | Untreated (new) | 4.1 ±0.259 (2–6) | |
| Relapse | 4.2 ±0.330 (4–5) | ||
| Defaulter | 4.9 ±0.150 (4–5) |
Fig 1Location of pain in the patients with ENL.
*value is among 31 males.
Fig 2Symptoms other than pain in patients with ENL.
Fig 3Frequency of the different skin lesions in patients with ENL.
Other clinical pictures in patients with ENL at enrolment.
| Number of skin lesions | number | % | |
| <5 | 3 | 6.5 | |
| 6–10 | 4 | 8.7 | |
| 11–20 | 18 | 39.1 | |
| 21–50 | 16 | 34.8 | |
| >50 | 5 | 10.9 | |
| Location of skin lesions | Head/neck | 29 | 63.0 |
| Trunk | 18 | 39.1 | |
| Upper limbs | 45 | 97.8 | |
| Lower limbs | 44 | 95.7 | |
| Nerve symptoms | Reduced Sensation | 23 | 50.0 |
| Paraesthesia | 6 | 13.0 | |
| Hyperaesthesia | 11 | 23.9 | |
| Weakness | 35 | 76.1 | |
| Nerve function impairment (NFI) | Old | 24 | 52.2 |
| New | 6 | 13.0 | |
| Organs involved in ENL | |||
| Oedema | Hand | 26 | 56.5 |
| Face | 16 | 34.8 | |
| Lower limbs | 22 | 47.8 | |
| Dactylitis | 1 | 2.2 | |
| Large joint Arthritis | 7 | 15.2 | |
| Small joint arthritis | 13 | 28.3 | |
| Conjunctivitis | 2 | 4.3 | |
| Lagophthalmos | 1 | 2.2 | |
| Scleritis | 4 | 8.7 | |
| Lymph node | 7 | 15.2 |
Fig 4H &E stained skin biopsies: A. Histopathology of LL lesion without reaction: reticular dermal infiltration of lymphocytes, flat epidermis and foamy histiocytes.B. Histopathology of EN lesion: flat granular PMN infiltration with perivascular lymphocytic infiltration and lobar panniculitis. H & E staining x40.
Histopathological features of study subjects before and after treatment.
| Diagnosis | Before treatment n (%) | After treatment n (%) | ||||
|---|---|---|---|---|---|---|
| ENL | LL (n = 21) | P-value | ENL (n = 33) | LL (n = 21) | P-value | |
| Neutrophil infiltration | 20 (58.8) | 3 (14.3) | 0.004 | 5 (15.2) | 7 (33.3) | 0.058 |
| Lymphocytes | 34 (100.0) | 21 (100.0) | 0.984 | 20 (60.6) | 21 (100.0) | 0.006 |
| Foamy histiocytes | 29 (85.3) | 20 (95.3) | 0.627 | 14 (42.2) | 18 (85.7%) | 0.001 |
| Eosinophils and mast cells | 6 (17.6) | 5 (23.8) | 0.284 | 1 (3.0) | 4 (19.0) | 0.06 |
| Vasculitis | 5 (14.7) | 4 (19.0) | 0.079 | 2 (6.1) | 2 (9.5) | 0.841 |
| Necrosis | 2 (5.9) | 2 (9.5) | 0.068 | 2 (6.1) | 10 (47.6) | 0.004 |
| Panniculitis | 10 (62.5)δ | 0 (0) | <0.001 | 6(75.0%)ε | 0 (0) | 0.001 |
δ; n = 16. ε; n = 8.
* statistical test significant at P = 0.05.